https://www.selleckchem.com/pr....oducts/phosphoramido
In younger patients and those without serious comorbidities, polatuzumab vedotin-BR may serve as bridging therapy to more intensive therapies with reasonable efficacy and tolerability. Polatuzumab vedotin is currently being studied in a randomized trial in the front line setting in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).Introduction The human liver is the center for drug metabolism and detoxification and is, therefore, constantly exposed to toxic chemicals. Th
Like
Comment
Share
